This suggests that patients with early-stage disease may respond to URLC10 CTL induction to a greater extent than patients with advanced disease, but DEPDC1- and MPHOSPH1-specific CTL induction was 60% in this study, which was similar to that seen after four vaccination doses in a previous study in patients with advanced bladder cancer [13]. Here, LY6K is linked to urinary bladder cancer.